Literature DB >> 10216319

Expression, purification and crystallization of recombinant human TRAIL.

S S Cha1, H C Shin, K Y Choi, B H Oh.   

Abstract

TRAIL (also known as Apo-2L) belongs to the tumour necrosis factor (TNF) cytokine family and induces rapid apoptosis in a wide variety of tumour cell lines upon binding to the death-signalling receptors on the cell membrane. Normal cells are resistant to TRAIL, owing to the expression of decoy receptors which lack functional death domains and antagonize TRAIL-induced apoptosis. Soluble and functional human TRAIL, expressed in Escherichia coli and refolded into a functional form, has been crystallized. The crystals belong to space group P63 with unit-cell dimensions a = b = 65.61, c = 131. 70 A. The asymmetric unit contains two molecules of TRAIL, with a crystal volume per protein mass (Vm) of 2.41 A3 Da-1 and a solvent content of about 42% by volume. A native and a platinum-derivative data set to 2.8 and 3.5 A resolution, respectively, were obtained from frozen crystals. Structure determination by a combined molecular replacement and isomorphous replacement method is in progress.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216319     DOI: 10.1107/s090744499900164x

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  3 in total

1.  A simplified method for the efficient purification and refolding of recombinant human TRAIL.

Authors:  Zhenjiang Zhang; Su Bin Hahn; Thong M Cao; Michael R King
Journal:  Biotechnol Prog       Date:  2020-05-11

2.  Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87.

Authors:  X C Wei; X J Wang; K Chen; L Zhang; Y Liang; X L Lin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2.

Authors:  I-K Kim; Y-K Jung; D-Y Noh; Y-S Song; C-H Choi; B-H Oh; E S Masuda; Y-K Jung
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.